SCHEMBL31573170

SCHEMBL31573170

C[C@@H](CC#N)Nc1cc(CN2C(=O)N(c3ccc4c(c3)N(C)CC4(C)C)C(=O)C2(C)C)ccn1

nearest known ligand 0.50

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 18/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31572912 0.90 IGF1R (0.48) IGF1R
SCHEMBL31572970 0.90 IGF1R (0.61) IGF1R
SCHEMBL31572954 0.89 IGF1R (0.53) IGF1R
SCHEMBL31572982 0.84 IGF1R (0.47) IGF1R
SCHEMBL31330597 0.83 IGF1R (0.47) IGF1R
SCHEMBL31572962 0.82 IGF1R (0.60) IGF1R
SCHEMBL31330670 0.81 IGF1R (0.59) IGF1R
SCHEMBL5484581 0.81 IGF1R (0.47) IGF1R
SCHEMBL5480870 0.80 IGF1R (0.51) IGF1R
SCHEMBL31572893 0.80 IGF1R (0.57) IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250145585-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE HORIZON THERAPEUTICS IRELAND DAC (IE) 2025-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250145585-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE IGF1R, TSHR, TRHR IGF1R 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.